| Expression pattern: |
UP |
| Associated gene: |
USP28, AGO2 |
| Associated microRNA: |
miR-655-3p |
| Biological function: |
promotes lenvatinib resistance in HCC; promotes tumor growth under lenvatinib treatment |
| Molecular mechanism: |
ceRNA mechanism: circMED27 sponges miR-655-3p to upregulate USP28; association with AGO2 complex |
| Biological pathway or process: |
ceRNA regulation (promotes); drug resistance (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Survival Analysis; Cohort Study; FISH / smFISH; Luciferase Reporter Assay; circRIP; RIP (RNA Immunoprecipitation); Transfection; CCK8; Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model |
| Clinical significance: |
Higher levels of circMED27 were correlated with bad clinical characteristics and poor prognoses of patients with HCC; serum exosomal circMED27 is an independent predictor for OS and postoperative recurrence; high circMED27 predicts shorter PFS under lenvatinib |
| Description: |
circMED27 is upregulated in HCC tissues and serum exosomes and is associated with worse prognosis. Functionally, circMED27 promotes lenvatinib resistance by acting as a ceRNA that sponges miR-655-3p, thereby increasing USP28 expression, with predominant cytoplasmic localization and validation in HCC cells and xenografts. |
| Confidence score: |
0.8062 |